U.S. markets close in 30 minutes
  • S&P 500

    4,519.30
    -57.80 (-1.26%)
     
  • Dow 30

    34,460.66
    -179.13 (-0.52%)
     
  • Nasdaq

    15,006.80
    -374.52 (-2.43%)
     
  • Russell 2000

    2,148.71
    -57.63 (-2.61%)
     
  • Crude Oil

    65.73
    -0.77 (-1.16%)
     
  • Gold

    1,786.70
    +24.00 (+1.36%)
     
  • Silver

    22.55
    +0.23 (+1.03%)
     
  • EUR/USD

    1.1312
    +0.0006 (+0.06%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3233
    -0.0069 (-0.52%)
     
  • USD/JPY

    112.7610
    -0.4480 (-0.40%)
     
  • BTC-USD

    53,186.18
    -3,865.43 (-6.78%)
     
  • CMC Crypto 200

    1,346.18
    -95.58 (-6.63%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value

·2 min read
Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A clinical trial showed that patients with the greatest reduction in a specific bacterium saw the greatest cognitive benefit from the South San Francisco company's drug, but the trail failed to meet its primary targets.